Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells

Cyclin B1 is the regulatory subunit of M-phase promoting factor, and proper regulation of cyclin B1 is essential for the initiation of mitosis. Increasing evidence indicates that the deregulation of cyclin B1 is involved in neoplastic transformation, suggesting the suppression of cyclin B1 could be an attractive strategy for antiproliferative therapy. In the present work, we analysed the impact of small interfering RNAs (siRNAs) targeted to cyclin B1 on different human tumor cell lines. Cyclin B1 siRNAs reduced the protein level of cyclin B1 in HeLa, MCF-7, BT-474 and MDA-MB-435 tumor cells and efficiently reduced the kinase activity of Cdc2/cyclin B1 in HeLa cells. siRNA-treated cells were arrested in G2/M phase in all tumor cell lines tested. Proliferation of tumor cells from different origins was suppressed by 50–80% 48 h after transfection and apoptosis was increased from 5 to 40–50%. Furthermore, tumor cells showed less colony-forming ability after siRNA treatment. In contrast, primary human umbilical vein endothelial cells exhibited only a slight change in cell cycle, and neither apoptosis nor clear inhibition of proliferation was observed after cyclin B1 siRNA treatment for 48 h. These results indicate that siRNAs against cyclin B1 could become a powerful antiproliferative tool in future antitumor therapy.

[1]  S. Takeno,et al.  Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma , 2002, Cancer.

[2]  Thomas Tuschl,et al.  Expanding small RNA interference , 2002, Nature Biotechnology.

[3]  E. Ortega,et al.  Oncogenic H-ras induces cyclin B1 expression in a p53-independent manner. , 2002, Mutation research.

[4]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[5]  E. Nigg,et al.  Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. , 1991, The EMBO journal.

[6]  Yasuo Watanabe,et al.  Clinical relevance of cyclin B1 overexpression in laryngeal squamous cell carcinoma. , 2002, Cancer letters.

[7]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[8]  Jane A. Endicott,et al.  Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor , 2002, Nature Structural Biology.

[9]  Jürgen Bereiter-Hahn,et al.  Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. , 2002, Journal of the National Cancer Institute.

[10]  H. Lane,et al.  Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes , 1996, The Journal of cell biology.

[11]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Meijer,et al.  p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol , 2002, Oncogene.

[13]  P. Hieter,et al.  Overexpression of B-type cyclins alters chromosomal segregation , 2002, Oncogene.

[14]  D. Morgan,et al.  Nuclear Localization of Cyclin B1 Controls Mitotic Entry After DNA Damage , 1998, The Journal of cell biology.

[15]  J. Bereiter-Hahn,et al.  Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1 , 2002, Oncogene.